HRP20130072T1 - Supstituirani (oksazolidinon-5-il-metil)-2-tiofen-karboksamidi i njihova uporaba u podruäśju koagulacije krvi - Google Patents
Supstituirani (oksazolidinon-5-il-metil)-2-tiofen-karboksamidi i njihova uporaba u podruäśju koagulacije krvi Download PDFInfo
- Publication number
- HRP20130072T1 HRP20130072T1 HRP20130072AT HRP20130072T HRP20130072T1 HR P20130072 T1 HRP20130072 T1 HR P20130072T1 HR P20130072A T HRP20130072A T HR P20130072AT HR P20130072 T HRP20130072 T HR P20130072T HR P20130072 T1 HRP20130072 T1 HR P20130072T1
- Authority
- HR
- Croatia
- Prior art keywords
- ring
- methyl
- represents hydrogen
- ethyl
- solvates
- Prior art date
Links
- 230000023555 blood coagulation Effects 0.000 title claims 3
- UYGKMSUDBLULNG-UHFFFAOYSA-N 3-[(2-oxo-1,3-oxazolidin-5-yl)methyl]thiophene-2-carboxamide Chemical class S1C=CC(CC2OC(=O)NC2)=C1C(=O)N UYGKMSUDBLULNG-UHFFFAOYSA-N 0.000 title 1
- -1 trifluoromethoxy, methyl Chemical group 0.000 claims 69
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 15
- 239000012453 solvate Substances 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 238000011321 prophylaxis Methods 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 230000009424 thromboembolic effect Effects 0.000 claims 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
- 206010053159 Organ failure Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Chemical group 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 230000004768 organ dysfunction Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007028319A DE102007028319A1 (de) | 2007-06-20 | 2007-06-20 | Substituierte Oxazolidinone und ihre Verwendung |
| PCT/EP2008/004562 WO2008155032A1 (de) | 2007-06-20 | 2008-06-07 | Substituierte (oxazolidinon-5-yl-methyl) -2-thiophen-carboxamide und ihre verwendung im gebiet der blutgerinnung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130072T1 true HRP20130072T1 (hr) | 2013-02-28 |
Family
ID=39731148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130072AT HRP20130072T1 (hr) | 2007-06-20 | 2013-01-28 | Supstituirani (oksazolidinon-5-il-metil)-2-tiofen-karboksamidi i njihova uporaba u podruäśju koagulacije krvi |
Country Status (43)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006039589A1 (de) * | 2006-08-24 | 2008-03-06 | Bayer Healthcare Ag | Aminoacyl-Prodrugs II |
| DE102007028407A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028319A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102010028362A1 (de) | 2010-04-29 | 2011-11-03 | Bayer Schering Pharma Aktiengesellschaft | Herstellverfahren |
| CN102464658B (zh) * | 2010-11-03 | 2014-04-16 | 天津药物研究院 | 噁唑烷酮衍生物及其制备方法和用途 |
| EP2665751A1 (de) | 2011-01-19 | 2013-11-27 | Bayer Intellectual Property GmbH | Bindung von proteinen an hemmer von gerinnungsfaktoren |
| CN103626749A (zh) * | 2012-08-21 | 2014-03-12 | 苏州泽璟生物制药有限公司 | 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途 |
| CN103232446B (zh) * | 2013-05-17 | 2015-09-23 | 天津药物研究院 | 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 |
| CN103242307B (zh) * | 2013-05-17 | 2015-08-12 | 天津药物研究院有限公司 | 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途 |
| CN104163819A (zh) * | 2013-05-17 | 2014-11-26 | 天津药物研究院 | 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| DE4319041A1 (de) | 1992-10-23 | 1994-04-28 | Bayer Ag | Trisubstituierte Biphenyle |
| CZ130999A3 (cs) | 1996-10-14 | 1999-07-14 | Bayer Aktiengesellschaft | Heterocyklylmethyl-substituované deriváty pyrazolu, způsob jejich výroby, farmaceutické prostředky tyto látky obsahující a jejich použití pro výrobu léčiv |
| DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
| DE19649460A1 (de) | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834045A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
| US6259067B1 (en) | 1998-10-16 | 2001-07-10 | Medical Solutions, Inc. | Temperature control system and method for heating and maintaining medical items at desired temperatures |
| DE19920352A1 (de) | 1999-05-04 | 2000-11-09 | Bayer Ag | Substituiertes Pyrazolderivat |
| JP2003502314A (ja) | 1999-06-14 | 2003-01-21 | イーライ・リリー・アンド・カンパニー | 化合物 |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| WO2001046185A1 (en) * | 1999-12-21 | 2001-06-28 | Pharmacia & Upjohn Company | Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents |
| DE19962924A1 (de) * | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| GB0114004D0 (en) | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| GB0114005D0 (en) | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| TWI257389B (en) | 2001-06-12 | 2006-07-01 | Lilly Co Eli | Pharmaceutical compound |
| US7365205B2 (en) | 2001-06-20 | 2008-04-29 | Daiichi Sankyo Company, Limited | Diamine derivatives |
| DE10129725A1 (de) * | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
| JP2005520782A (ja) * | 2001-07-12 | 2005-07-14 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 向上した水溶解度を有するアミド含有化合物およびアミド含有化合物の水溶解度を向上させる方法 |
| CN104744461A (zh) | 2001-09-21 | 2015-07-01 | 百时美施贵宝公司 | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 |
| TW200738672A (en) | 2001-12-10 | 2007-10-16 | Bristol Myers Squibb Co | Intermediated for the preparation of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones |
| PE20040804A1 (es) | 2002-12-19 | 2004-12-31 | Boehringer Ingelheim Pharma | DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa |
| US7205318B2 (en) | 2003-03-18 | 2007-04-17 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors |
| DE10322469A1 (de) | 2003-05-19 | 2004-12-16 | Bayer Healthcare Ag | Heterocyclische Verbindungen |
| US7265140B2 (en) * | 2003-09-23 | 2007-09-04 | Pfizer Inc | Acyloxymethylcarbamate prodrugs of oxazolidinones |
| CN102002059B (zh) | 2003-11-12 | 2012-06-13 | 第一三共株式会社 | 噻唑衍生物的制备方法 |
| DE10355461A1 (de) * | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
| JP2005179272A (ja) | 2003-12-19 | 2005-07-07 | Yamanouchi Pharmaceut Co Ltd | カルボキサミド誘導体のマロン酸塩結晶 |
| DE102004002044A1 (de) * | 2004-01-15 | 2005-08-04 | Bayer Healthcare Ag | Herstellverfahren |
| GB0405272D0 (en) | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
| US7521470B2 (en) * | 2004-06-18 | 2009-04-21 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| US20060069260A1 (en) | 2004-09-28 | 2006-03-30 | Huiping Zhang | Preparation of N-aryl pyridones |
| DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| US20090076015A1 (en) | 2005-03-31 | 2009-03-19 | Hidemitsu Nishida | Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring |
| US20080221063A1 (en) | 2005-07-08 | 2008-09-11 | Astrazeneca Ab | Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa |
| AR057976A1 (es) * | 2005-08-29 | 2008-01-09 | Boehringer Ingelheim Int | Biarilos sustituidos y su uso como medicamentos. |
| DE102005047558A1 (de) * | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
| DE102005050498A1 (de) | 2005-10-21 | 2007-06-06 | Bayer Healthcare Aktiengesellschaft | Cyclopropylessigsäure-Derivate und ihre Verwendung |
| DE102005050375A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Tetrazol-Derivate und ihre Verwendung |
| DE102005050497A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Difluorphenol-Derivate und ihre Verwendung |
| DE102005050376A1 (de) | 2005-10-21 | 2007-05-31 | Bayer Healthcare Ag | Dicarbonsäure-Derivate und ihre Verwendung |
| DE102005050377A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
| DE102006025314A1 (de) * | 2006-05-31 | 2007-12-06 | Bayer Healthcare Ag | Arylsubstituierte Heterozyklen und ihre Verwendung |
| DE102006039589A1 (de) * | 2006-08-24 | 2008-03-06 | Bayer Healthcare Ag | Aminoacyl-Prodrugs II |
| DE102007028319A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028406A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028407A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
-
2007
- 2007-06-20 DE DE102007028319A patent/DE102007028319A1/de not_active Withdrawn
-
2008
- 2008-06-06 UY UY31133A patent/UY31133A1/es not_active Application Discontinuation
- 2008-06-07 UA UAA201000550A patent/UA98793C2/ru unknown
- 2008-06-07 AU AU2008266525A patent/AU2008266525B8/en not_active Ceased
- 2008-06-07 DK DK08773372.1T patent/DK2170877T5/da active
- 2008-06-07 CN CN2008801031298A patent/CN101821259B/zh not_active Expired - Fee Related
- 2008-06-07 PL PL08773372T patent/PL2170877T3/pl unknown
- 2008-06-07 SI SI200830882T patent/SI2170877T1/sl unknown
- 2008-06-07 CA CA2692166A patent/CA2692166C/en not_active Expired - Fee Related
- 2008-06-07 RU RU2010101307/04A patent/RU2481345C2/ru not_active IP Right Cessation
- 2008-06-07 JP JP2010512559A patent/JP5537421B2/ja not_active Expired - Fee Related
- 2008-06-07 EP EP08773372A patent/EP2170877B1/de active Active
- 2008-06-07 WO PCT/EP2008/004562 patent/WO2008155032A1/de active Application Filing
- 2008-06-07 PT PT87733721T patent/PT2170877E/pt unknown
- 2008-06-07 KR KR1020097026556A patent/KR101535312B1/ko not_active IP Right Cessation
- 2008-06-07 SG SG2012045779A patent/SG182220A1/en unknown
- 2008-06-07 MX MX2009013711A patent/MX2009013711A/es active IP Right Grant
- 2008-06-07 BR BRPI0813736-6A2A patent/BRPI0813736A2/pt not_active Application Discontinuation
- 2008-06-07 RS RS20130039A patent/RS52639B/en unknown
- 2008-06-07 US US12/665,729 patent/US8383822B2/en not_active Expired - Fee Related
- 2008-06-07 MY MYPI20095462 patent/MY150931A/en unknown
- 2008-06-07 ES ES08773372T patent/ES2397799T3/es active Active
- 2008-06-07 NZ NZ581540A patent/NZ581540A/en not_active IP Right Cessation
- 2008-06-09 CL CL2008001691A patent/CL2008001691A1/es unknown
- 2008-06-10 PE PE2008000978A patent/PE20090332A1/es not_active Application Discontinuation
- 2008-06-11 PA PA20088784301A patent/PA8784301A1/es unknown
- 2008-06-12 AR ARP080102515A patent/AR066981A1/es not_active Application Discontinuation
- 2008-06-17 JO JO2008282A patent/JO2798B1/en active
- 2008-06-19 TW TW097122783A patent/TWI413642B/zh not_active IP Right Cessation
- 2008-06-19 AR ARP080102607A patent/AR067057A1/es not_active Application Discontinuation
-
2009
- 2009-11-26 IL IL202351A patent/IL202351A/en not_active IP Right Cessation
- 2009-11-30 TN TNP2009000503A patent/TN2009000503A1/fr unknown
- 2009-12-15 SV SV2009003435A patent/SV2009003435A/es unknown
- 2009-12-15 CU CU20090216A patent/CU23820A3/es active IP Right Grant
- 2009-12-15 GT GT200900319A patent/GT200900319A/es unknown
- 2009-12-15 DO DO2009000285A patent/DOP2009000285A/es unknown
- 2009-12-15 CR CR11168A patent/CR11168A/es not_active Application Discontinuation
- 2009-12-15 HN HN2009003424A patent/HN2009003424A/es unknown
- 2009-12-15 EC EC2009009807A patent/ECSP099807A/es unknown
- 2009-12-16 CO CO09144220A patent/CO6251281A2/es active IP Right Grant
-
2010
- 2010-01-19 MA MA32539A patent/MA31535B1/fr unknown
-
2011
- 2011-02-22 HK HK11101717.7A patent/HK1147991A1/xx not_active IP Right Cessation
-
2013
- 2013-01-28 HR HRP20130072AT patent/HRP20130072T1/hr unknown
- 2013-02-01 CY CY20131100095T patent/CY1113580T1/el unknown
- 2013-02-19 US US13/770,270 patent/US8846934B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130072T1 (hr) | Supstituirani (oksazolidinon-5-il-metil)-2-tiofen-karboksamidi i njihova uporaba u podruäśju koagulacije krvi | |
| TWI480272B (zh) | 藉由５，６－二氫－１ｈ－吡啶－２－酮與一或多種其他抗病毒化合物的組合物抑制ｃ型肝炎病毒的方法 | |
| ES2598404T3 (es) | Derivados de pirimidina para la prevención de infección por el VIH | |
| WO2002012189A1 (fr) | Composes amide bicycliques condenses et utilisations medicales associees | |
| CN106573914A (zh) | 作为激酶抑制剂的吡唑基‑脲 | |
| BRPI0316595B1 (pt) | composto, método para a preparação de compostos, composição farmacêutica e usos de um composto | |
| CN102239164A (zh) | 2h-色烯化合物及其衍生物 | |
| JP2015155445A (ja) | ｐ３８ＭＡＰキナーゼ阻害剤としての１−ピラゾリル−３−（４−（（２−アニリノピリミジン−４−イル）オキシ）ナフタレン−１−イル）尿素 | |
| DK1942108T3 (da) | Forbindelse indeholdende basisk gruppe samt anvendelse deraf | |
| RU2011102444A (ru) | Производные 1,2-дигидроциклобутендиона в качестве ингибиторов фосфорибозилтрансферазы никотинамида | |
| JPWO2006035876A1 (ja) | 関節リウマチの予防及び／又は治療薬 | |
| JP2003306481A5 (de) | ||
| JP2007522142A5 (de) | ||
| JP2017522339A (ja) | ２−アミノ−ベンゾイミダゾール誘導体ならびにこれらの５−リポキシゲナーゼおよび／またはプロスタグランジンｅシンターゼ阻害剤としての使用 | |
| JP2017511374A (ja) | Ｒｎａおよび／またはｄｎａ含有ウイルスにより引き起こされる疾患、および合併症の治療および予防のための薬剤としての、アミド化合物、その調製方法、ならびに使用。 | |
| Yang et al. | Discovery of 4-oxo-N-phenyl-1, 4-dihydroquinoline-3-carboxamide derivatives as novel anti-inflammatory agents for the treatment of acute lung injury and sepsis | |
| RU2010101303A (ru) | Замещенные (оксазолидинон-5-ил-метил)-2-тиофен-карбоксамиды и их применение в сфере свертывания крови | |
| CN110590660B (zh) | 一种喹啉甲酰胺类化合物及其制备方法与抗肠道病毒71型的应用 | |
| CN105541700B (zh) | 一种含哌啶酮结构的单羰基姜黄素类似物及应用 | |
| CN103768073A (zh) | 具有双腙结构的甾体衍生物作为抗病毒药物的应用 | |
| JPWO2007026737A1 (ja) | 関節リウマチの予防及び／又は治療法 | |
| TWI492920B (zh) | 水楊酸苯胺衍生小分子之醫藥組合物及其製備與醫藥用途 | |
| Babar et al. | N, N‐Diarylsulfonamide Reduces Proinflammatory Cytokine Interleukin‐6 Levels in Cells through Nuclear Factor‐κB Regulation | |
| CN101137379B (zh) | 用于治疗医学病症的cxcr4拮抗剂 | |
| WO2023104213A1 (zh) | 环状双苄基四氢异喹啉类化合物及其制备方法和应用 |